Premium
Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy
Author(s) -
Wang Wei,
Hao Yuhao,
Liu Yusheng,
Li Rui,
Huang DaBing,
Pan YueYin
Publication year - 2020
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1654
Subject(s) - medicine , nanomedicine , lung cancer , nanocarriers , immunotherapy , cancer , drug , drug delivery , drug resistance , metastasis , chemotherapy , disease , oncology , pharmacology , nanotechnology , biology , materials science , nanoparticle , microbiology and biotechnology
Lung cancer is considered to cause the most cancer‐related deaths worldwide. Due to the deficiency in early‐stage diagnostics and local invasion or distant metastasis, the first line of treatment for most patients unsuitable for surgery is chemotherapy, targeted therapy or immunotherapy. Nanocarriers with the function of improving drug solubility, in vivo stability, drug distribution in the body, and sustained and targeted delivery, can effectively improve the effect of drug treatment and reduce toxic and side effects, and have been used in clinical treatment for lung cancer and many types of cancers. Here, we review nanoparticle (NP) formulation for lung cancer treatment including liposomes, polymers, and inorganic NPs via systemic and inhaled administration, and highlight the works of overcoming drug resistance and improving cancer immunotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease